Delafloxacin - Melinta Therapeutics

Drug Profile

Delafloxacin - Melinta Therapeutics

Alternative Names: ABT-492; Baxdela; Quofenix; RX-3341; RX-3341-83; WQ-3034

Latest Information Update: 29 May 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Wakunaga Pharmaceutical
  • Developer Abbott Laboratories; Eurofarma; Melinta Therapeutics; Menarini
  • Class Antibacterials; Azetidines; Fluoroquinolones; Pyridines; Small molecules
  • Mechanism of Action DNA gyrase inhibitors; DNA topoisomerase IV inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Skin and soft tissue infections
  • Phase III Community-acquired pneumonia
  • Phase I Urinary tract infections
  • Discontinued Acute exacerbations of chronic bronchitis; Anthrax; Gonorrhoea; Intra-abdominal infections

Most Recent Events

  • 04 May 2018 Preregistration for Skin and soft tissue infections in Peru (IV)
  • 04 May 2018 Preregistration for Skin and soft tissue infections in Peru (PO)
  • 30 Apr 2018 Melinta Therapeutics initiates enrolment in a phase I trial for Pneumonia (In volunteers) in USA (NCT03534622)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top